
Insights Into Testing Protocols and Treatment Pathways for NTRK Fusion-Positive Cancers 2021
Perspectives of community physicians from across the US on optimal integration and side effect management of novel therapies

Faculty Chair
Lee Schwartzberg, MD, FACP
West Cancer Center, Memphis, TN
More Information
- Virtual series
REPORT SNAPSHOT
- NTRK Gene Fusions as Oncogenic Drivers
- Treatment of Thyroid/Salivary Gland Cancers
- Consensus Pathway Discussion: Thyroid/Salivary Gland Cancers
- Treatment of Lung Cancer
- Consensus Pathway Discussion: Lung Cancer
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection was accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprised 10–15 medical oncologists